We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





US ‘Operation Warp Speed’ To Ready 300 Million Vaccine Doses by End Of 2020

By HospiMedica International staff writers
Posted on 01 May 2020
The Trump administration is reportedly bringing biotech, pharma and federal agencies together in a project dubbed “Operation Warp Speed” that aims to cut the COVID-19 vaccine’s development time and deliver 100 million doses in the US by the end of the year.

The World Health Organization estimates more than 100 coronavirus vaccine candidates to be currently in development. More...
Experts do not expect a vaccine to be ready for at least 12 to 18 months. Under project “Operation Warp Speed”, pharmaceutical companies, government agencies and the military will work together to cut that time by up to eight months. The administration will help biopharma companies coordinate their individual efforts by providing assistance through federal agencies and the US military. The project is similar to the Manhattan Project-style joint initiative which brought different sectors together to develop the nation’s atomic bomb.

The officials are looking at a master trial protocol that would allow researchers to simultaneously study different vaccines instead of studying each vaccine separately through independent studies by pharmaceutical companies. The administration plans to speed up distribution by scaling up manufacturing capabilities as the vaccines enter large human trials. The goal of project “Operation Warp Speed” is to have 300 million doses of vaccine available by January.

In a media interview, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases and a key member of the White House Coronavirus Task Force, said that developing a vaccine to combat the coronavirus outbreak by January was “doable.” Dr. Fauci said that it was possible to ready hundreds of millions of doses of a coronavirus vaccine by January. However, meeting the January deadline will ultimately depend upon whether the results of trials prove that the vaccine works.

“We're going to start ramping up production with the companies involved and you do that at risk, in other words you don't wait until you get an answer before you start manufacturing, you at risk, proactively, start making it, assuming it's going to work,” said Dr. Fauci. “And if it does, then you can scale up and hopefully get to that timeline.”


Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Gold Member
Blood Gas Analyzer
i-Check200
Digital Radiography System (Ceiling Free)
Digix CF Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Critical Care

view channel
Image: Tubes attached to this artificial lung are connected to the patient\'s neck or chest, allowing blood to circulate and get oxygen while the patient is conscious. (Image Credit: Carnegie MellonImage: Tubes attached to this artificial lung are connected to the patient\'s neck or chest, allowing blood to circulate and get oxygen while the patient is conscious. (Image Credit: Carnegie Mellon University)University)

Portable Artificial Lung Technology Could Reshape Care for Chronic Lung Disease

Chronic lung disease can leave patients dependent on prolonged mechanical ventilation or awaiting transplantation, both of which carry substantial morbidity and healthcare costs. Ventilatory support may... Read more

Surgical Techniques

view channel
Image: The thin foetoscope is guided through the abdominal wall to the placenta. Small magnets in its tip react to an externally generated magnetic field, enabling the instrument to be bent with precision. The robotic platform is designed to occlude shared blood vessels in the placenta of twins with twin-to-twin transfusion syndrome. (Image Credit: created with BioRender.com, ETH Zurich)

Robotic Platform Advances Fetoscopic Treatment of Twin-to-Twin Transfusion Syndrome

Twin-to-twin transfusion syndrome is a life-threatening complication in monochorionic twin pregnancies caused by unbalanced placental blood flow. Definitive treatment requires endoscopic laser coagulation... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.